


9-27-04

216

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR
ENCLOSED HERewith ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON
SEP. 24 2004 AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR
PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker



PATENT
Attorney's Docket No.: 00065.01R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hale et al.
Serial No.: 10/712,365
Filed: 11/12/2003
Title: DIURETIC AEROSOLS AND METHODS OF MAKING AND USING THEM

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

SEP. 24 2004

Date: _____


Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation
1001 East Meadow Circle
Palo Alto, CA 94303
TEL: (650) 687-3905
FAX: (650) 687-3999



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/712,365	
	Filing Date	11/12/2003	
	First Named Inventor	Ron L. Hale	
	Art Unit	Not yet known	
	Examiner Name	To be assigned	
Total Number of Pages in This Submission		Attorney Docket Number	00065.01R

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Info. Discl. Statemetn (2 pp.) Form 1449 (3 copies, 4 pages each) Copy of 91 references Return Postcard	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Elaine C. Stracker, Ph.D., J.D. Telephone (650)-687-3905	
Signature		
Date	SEP. 24 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the			
Typed or printed name	Elaine C. Stracker		
Signature		Date	SEP. 24 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

	1.	08/04/2003	10/633,876	Hale et al.			
	2.	08/04/2003	10/633,877	Hale et al.			
	3.	12/30/2003	10/749,537	Rabinowitz et al.			
	4.	12/30/2003	10/749,539	Rabinowitz et al.			
	5.	01/27/2004	10/766,149	Rabinowitz et al.			
	6.	01/27/2004	10/766,279	Rabinowitz et al.			
	7.	01/27/2004	10/766,566	Rabinowitz et al.			
	8.	01/27/2004	10/766,574	Rabinowitz et al.			
	9.	01/27/2004	10/766,634	Rabinowitz et al.			
	10.	01/27/2004	10/766,647	Rabinowitz et al.			
	11.	01/28/2004	10/767,115	Rabinowitz et al.			
	12.	01/29/2004	10/768,205	Rabinowitz et al.			
	13.	01/29/2004	10/768,220	Rabinowitz et al.			
	14.	01/29/2004	10/768,281	Rabinowitz et al.			
	15.	01/29/2004	10/768,293	Rabinowitz et al.			
	16.	01/30/2004	10/769,046	Rabinowitz et al.			
	17.	01/30/2004	10/769,051	Rabinowitz et al.			
	18.	01/29/2004	10/769,157	Rabinowitz et al.			
	19.	01/29/2004	10/769,197	Rabinowitz et al.			
	20.	02/09/2004	10/775,583	Rabinowitz et al.			
	21.	02/09/2004	10/775,586	Rabinowitz et al.			
	22.	03/03/2004	10/791,915	Hale et al.			
	23.	03/03/2004	10/792,001	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

	24.	03/03/2004	10/792,012	Hale et al.			
	25.	03/03/2004	10/792,013	Rabinowitz et al.			
	26.	03/03/2004	10/792,096	Hale et al.			
	27.	03/03/2004	10/792,239	Hale et al.			
	28.	03/31/2004	10/813,721	Rabinowitz et al.			
	29.	03/31/2004	10/813,722	Rabinowitz et al.			
	30.	03/31/2004	10/814,690	Rabinowitz et al.			
	31.	03/31/2004	10/814,998	Rabinowitz et al.			
	32.	04/01/2004	10/815,527	Rabinowitz et al.			
	33.	04/01/2004	10/816,407	Rabinowitz et al.			
	34.	04/01/2004	10/816,492	Rabinowitz et al.			
	35.	04/01/2004	10/816,567	Rabinowitz et al.			
	36.	08/04/2004	10/912,462	Hale et al.			
	37.	01/23/2003	US 2003/0015196	Hodges et al.			
	38.	04/03/2003	US 2003/0062042	Wensley et al.			
	39.	11/13/2003	US 2003/0209240	Hale et al.			
	40.	01/02/2003	US 2003/0000518	Rabinowitz et al.			
	41.	01/09/2003	US 2003/0005924	Rabinowitz et al.			
	42.	01/09/2003	US 2003/0005925	Hale et al.			
	43.	01/09/2003	US 2003/0007933	Rabinowitz et al.			
	44.	01/09/2003	US 2003/0007934	Rabinowitz et al.			
	45.	01/16/2003	US 2003/0012737	Rabinowitz et al.			
	46.	01/16/2003	US 2003/0012738	Rabinowitz et al.			
	47.	1/16/2003	US 2003/0012740	Rabinowitz et al.			
	48.	01/23/2003	US 2003/0015189	Rabinowitz et al.			
	49.	01/23/2003	US 2003/0015190	Rabinowitz et al.			
	50.	01/23/2003	US 2003/0017114	Rabinowitz et al.			
	51.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
	52.	01/23/2003	US 2003/0017116	Rabinowitz et al.			
	53.	01/23/2003	US 2003/0017117	Rabinowitz et al.			
	54.	01/23/2003	US 2003/0017118	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

55.	01/23/2003	US 2003/0017119	Rabinowitz et al.			
56.	01/23/2003	US 2003/0017120	Rabinowitz et al.			
57.	1/30/2003	US 2003/0021753	Rabinowitz et al.			
58.	01/30/2003	US 2003/0021754	Rabinowitz et al.			
59.	01/30/2003	US 2003/0021755	Hale et al.			
60.	02/20/2003	US 2003/0035776	Hodges et al.			
61.	05/15/2003	US 2003/0091511	Rabinowitz et al.			
62.	05/27/2004	US 2004/010148	Hale et al.			
63.	07/31/2003	US 2003/0138382	Rabinowitz			
64.	11/06/2003	US 2003/0206869	Rabinowitz et al.			
65.	01/15/2004	US 2004/0009128	Rabinowitz et al.			
66.	05/20/2004	US 2004/0096402	Hodges et al.			
67.	05/27/2004	US 2004/0099269	Hale et al.			
68.	06/03/2004	US 2004/0105819	Hale et al.			
69.	07/01/2004	US 2004/0126326	Rabinowitz et al.			
70.	07/01/2004	US 2004/0126327	Rabinowitz et al.			
71.	07/01/2004	US 2004/0126328	Rabinowitz et al.			
72.	07/01/2004	US 2004/0126329	Rabinowitz et al.			
73.	07/01/2004	US 2004/0127481	Rabinowitz et al.			
74.	07/01/2004	US 2004/0127490	Rabinowitz et al.			
75.	08/12/2004	US 2004/0156788	Rabinowitz et al.			
76.	08/12/2004	US 2004/0156789	Rabinowitz et al.			
77.	8/12/2004	US 2004/0156790	Rabinowitz et al.			
78.	08/12/2004	US 2004/0156791	Rabinowitz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." <i>European Journal of Pharmaceutics and Biopharmaceutics</i> Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." <i>Cardiovascular Research</i> 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" <i>International Journal of Pharmaceutics</i> 204:35-41.
	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." <i>Am J Respir Crit Care Med</i> Vol. 161: 1963-1967.
	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." <i>Am. Rev. Respir. Dis.</i> 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." <i>Br J Clin Pharmacol</i> Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5' Monophosphate Airway Responsiveness with Inhaled Furosemide and Bumetanide in Asthma." <i>J. Allergy Clin. Immunol.</i> 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oxygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." <i>Am J Physiol Renal Physiol.</i> 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." <i>Journal of Pain and Symptom Management</i> Vol. 23 No.1: 73:76.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

	1.	08/04/2003	10/633,876	Hale et al.			
	2.	08/04/2003	10/633,877	Hale et al.			
	3.	12/30/2003	10/749,537	Rabinowitz et al.			
	4.	12/30/2003	10/749,539	Rabinowitz et al.			
	5.	01/27/2004	10/766,149	Rabinowitz et al.			
	6.	01/27/2004	10/766,279	Rabinowitz et al.			
	7.	01/27/2004	10/766,566	Rabinowitz et al.			
	8.	01/27/2004	10/766,574	Rabinowitz et al.			
	9.	01/27/2004	10/766,634	Rabinowitz et al.			
	10.	01/27/2004	10/766,647	Rabinowitz et al.			
	11.	01/28/2004	10/767,115	Rabinowitz et al.			
	12.	01/29/2004	10/768,205	Rabinowitz et al.			
	13.	01/29/2004	10/768,220	Rabinowitz et al.			
	14.	01/29/2004	10/768,281	Rabinowitz et al.			
	15.	01/29/2004	10/768,293	Rabinowitz et al.			
	16.	01/30/2004	10/769,046	Rabinowitz et al.			
	17.	01/30/2004	10/769,051	Rabinowitz et al.			
	18.	01/29/2004	10/769,157	Rabinowitz et al.			
	19.	01/29/2004	10/769,197	Rabinowitz et al.			
	20.	02/09/2004	10/775,583	Rabinowitz et al.			
	21.	02/09/2004	10/775,586	Rabinowitz et al.			
	22.	03/03/2004	10/791,915	Hale et al.			
	23.	03/03/2004	10/792,001	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

	24.	03/03/2004	10/792,012	Hale et al.			
	25.	03/03/2004	10/792,013	Rabinowitz et al.			
	26.	03/03/2004	10/792,096	Hale et al.			
	27.	03/03/2004	10/792,239	Hale et al.			
	28.	03/31/2004	10/813,721	Rabinowitz et al.			
	29.	03/31/2004	10/813,722	Rabinowitz et al.			
	30.	03/31/2004	10/814,690	Rabinowitz et al.			
	31.	03/31/2004	10/814,998	Rabinowitz et al.			
	32.	04/01/2004	10/815,527	Rabinowitz et al.			
	33.	04/01/2004	10/816,407	Rabinowitz et al.			
	34.	04/01/2004	10/816,492	Rabinowitz et al.			
	35.	04/01/2004	10/816,567	Rabinowitz et al.			
	36.	08/04/2004	10/912,462	Hale et al.			
	37.	01/23/2003	US 2003/0015196	Hodges et al.			
	38.	04/03/2003	US 2003/0062042	Wensley et al.			
	39.	11/13/2003	US 2003/0209240	Hale et al.			
	40.	01/02/2003	US 2003/0000518	Rabinowitz et al.			
	41.	01/09/2003	US 2003/0005924	Rabinowitz et al.			
	42.	01/09/2003	US 2003/0005925	Hale et al.			
	43.	01/09/2003	US 2003/0007933	Rabinowitz et al.			
	44.	01/09/2003	US 2003/0007934	Rabinowitz et al.			
	45.	01/16/2003	US 2003/0012737	Rabinowitz et al.			
	46.	01/16/2003	US 2003/0012738	Rabinowitz et al.			
	47.	1/16/2003	US 2003/0012740	Rabinowitz et al.			
	48.	01/23/2003	US 2003/0015189	Rabinowitz et al.			
	49.	01/23/2003	US 2003/0015190	Rabinowitz et al.			
	50.	01/23/2003	US 2003/0017114	Rabinowitz et al.			
	51.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
	52.	01/23/2003	US 2003/0017116	Rabinowitz et al.			
	53.	01/23/2003	US 2003/0017117	Rabinowitz et al.			
	54.	01/23/2003	US 2003/0017118	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

55.	01/23/2003	US 2003/0017119	Rabinowitz et al.			
56.	01/23/2003	US 2003/0017120	Rabinowitz et al.			
57.	1/30/2003	US 2003/0021753	Rabinowitz et al.			
58.	01/30/2003	US 2003/0021754	Rabinowitz et al.			
59.	01/30/2003	US 2003/0021755	Hale et al.			
60.	02/20/2003	US 2003/0035776	Hodges et al.			
61.	05/15/2003	US 2003/0091511	Rabinowitz et al.			
62.	05/27/2004	US 2004/010148	Hale et al.			
63.	07/31/2003	US 2003/0138382	Rabinowitz			
64.	11/06/2003	US 2003/0206869	Rabinowitz et al.			
65.	01/15/2004	US 2004/0009128	Rabinowitz et al.			
66.	05/20/2004	US 2004/0096402	Hodges et al.			
67.	05/27/2004	US 2004/0099269	Hale et al.			
68.	06/03/2004	US 2004/0105819	Hale et al.			
69.	07/01/2004	US 2004/0126326	Rabinowitz et al.			
70.	07/01/2004	US 2004/0126327	Rabinowitz et al.			
71.	07/01/2004	US 2004/0126328	Rabinowitz et al.			
72.	07/01/2004	US 2004/0126329	Rabinowitz et al.			
73.	07/01/2004	US 2004/0127481	Rabinowitz et al.			
74.	07/01/2004	US 2004/0127490	Rabinowitz et al.			
75.	08/12/2004	US 2004/0156788	Rabinowitz et al.			
76.	08/12/2004	US 2004/0156789	Rabinowitz et al.			
77.	8/12/2004	US 2004/0156790	Rabinowitz et al.			
78.	08/12/2004	US 2004/0156791	Rabinowitz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 00065.01R	Application Number: 10/712,365
	Applicant: HALE et al.	
	Filing Date: 11/12/2003	Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." <i>European Journal of Pharmaceutics and Biopharmaceutics</i> Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." <i>Cardiovascular Research</i> 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" <i>International Journal of Pharmaceutics</i> 204:35-41.
	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." <i>Am J Respir Crit Care Med</i> Vol. 161: 1963-1967.
	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." <i>Am. Rev. Respir. Dis.</i> 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." <i>Br J Clin Pharmacol</i> Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5' Monophosphate Airway Responsiveness with Inhaled Furosemide and Bumetanide in Asthma." <i>J. Allergy Clin. Immunol.</i> 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oxygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." <i>Am J Physiol Renal Physiol.</i> 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." <i>Journal of Pain and Symptom Management</i> Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

	1.	08/04/2003	10/633,876	Hale et al.			
	2.	08/04/2003	10/633,877	Hale et al.			
	3.	12/30/2003	10/749,537	Rabinowitz et al.			
	4.	12/30/2003	10/749,539	Rabinowitz et al.			
	5.	01/27/2004	10/766,149	Rabinowitz et al.			
	6.	01/27/2004	10/766,279	Rabinowitz et al.			
	7.	01/27/2004	10/766,566	Rabinowitz et al.			
	8.	01/27/2004	10/766,574	Rabinowitz et al.			
	9.	01/27/2004	10/766,634	Rabinowitz et al.			
	10.	01/27/2004	10/766,647	Rabinowitz et al.			
	11.	01/28/2004	10/767,115	Rabinowitz et al.			
	12.	01/29/2004	10/768,205	Rabinowitz et al.			
	13.	01/29/2004	10/768,220	Rabinowitz et al.			
	14.	01/29/2004	10/768,281	Rabinowitz et al.			
	15.	01/29/2004	10/768,293	Rabinowitz et al.			
	16.	01/30/2004	10/769,046	Rabinowitz et al.			
	17.	01/30/2004	10/769,051	Rabinowitz et al.			
	18.	01/29/2004	10/769,157	Rabinowitz et al.			
	19.	01/29/2004	10/769,197	Rabinowitz et al.			
	20.	02/09/2004	10/775,583	Rabinowitz et al.			
	21.	02/09/2004	10/775,586	Rabinowitz et al.			
	22.	03/03/2004	10/791,915	Hale et al.			
	23.	03/03/2004	10/792,001	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

	24.	03/03/2004	10/792,012	Hale et al.			
	25.	03/03/2004	10/792,013	Rabinowitz et al.			
	26.	03/03/2004	10/792,096	Hale et al.			
	27.	03/03/2004	10/792,239	Hale et al.			
	28.	03/31/2004	10/813,721	Rabinowitz et al.			
	29.	03/31/2004	10/813,722	Rabinowitz et al.			
	30.	03/31/2004	10/814,690	Rabinowitz et al.			
	31.	03/31/2004	10/814,998	Rabinowitz et al.			
	32.	04/01/2004	10/815,527	Rabinowitz et al.			
	33.	04/01/2004	10/816,407	Rabinowitz et al.			
	34.	04/01/2004	10/816,492	Rabinowitz et al.			
	35.	04/01/2004	10/816,567	Rabinowitz et al.			
	36.	08/04/2004	10/912,462	Hale et al.			
	37.	01/23/2003	US 2003/0015196	Hodges et al.			
	38.	04/03/2003	US 2003/0062042	Wensley et al.			
	39.	11/13/2003	US 2003/0209240	Hale et al.			
	40.	01/02/2003	US 2003/0000518	Rabinowitz et al.			
	41.	01/09/2003	US 2003/0005924	Rabinowitz et al.			
	42.	01/09/2003	US 2003/0005925	Hale et al.			
	43.	01/09/2003	US 2003/0007933	Rabinowitz et al.			
	44.	01/09/2003	US 2003/0007934	Rabinowitz et al.			
	45.	01/16/2003	US 2003/0012737	Rabinowitz et al.			
	46.	01/16/2003	US 2003/0012738	Rabinowitz et al.			
	47.	1/16/2003	US 2003/0012740	Rabinowitz et al.			
	48.	01/23/2003	US 2003/0015189	Rabinowitz et al.			
	49.	01/23/2003	US 2003/0015190	Rabinowitz et al.			
	50.	01/23/2003	US 2003/0017114	Rabinowitz et al.			
	51.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
	52.	01/23/2003	US 2003/0017116	Rabinowitz et al.			
	53.	01/23/2003	US 2003/0017117	Rabinowitz et al.			
	54.	01/23/2003	US 2003/0017118	Rabinowitz et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R

Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003

Group Art Unit: Unknown

55.	01/23/2003	US 2003/0017119	Rabinowitz et al.			
56.	01/23/2003	US 2003/0017120	Rabinowitz et al.			
57.	1/30/2003	US 2003/0021753	Rabinowitz et al.			
58.	01/30/2003	US 2003/0021754	Rabinowitz et al.			
59.	01/30/2003	US 2003/0021755	Hale et al.			
60.	02/20/2003	US 2003/0035776	Hodges et al.			
61.	05/15/2003	US 2003/0091511	Rabinowitz et al.			
62.	05/27/2004	US 2004/010148	Hale et al.			
63.	07/31/2003	US 2003/0138382	Rabinowitz			
64.	11/06/2003	US 2003/0206869	Rabinowitz et al.			
65.	01/15/2004	US 2004/0009128	Rabinowitz et al.			
66.	05/20/2004	US 2004/0096402	Hodges et al.			
67.	05/27/2004	US 2004/0099269	Hale et al.			
68.	06/03/2004	US 2004/0105819	Hale et al.			
69.	07/01/2004	US 2004/0126326	Rabinowitz et al.			
70.	07/01/2004	US 2004/0126327	Rabinowitz et al.			
71.	07/01/2004	US 2004/0126328	Rabinowitz et al.			
72.	07/01/2004	US 2004/0126329	Rabinowitz et al.			
73.	07/01/2004	US 2004/0127481	Rabinowitz et al.			
74.	07/01/2004	US 2004/0127490	Rabinowitz et al.			
75.	08/12/2004	US 2004/0156788	Rabinowitz et al.			
76.	08/12/2004	US 2004/0156789	Rabinowitz et al.			
77.	8/12/2004	US 2004/0156790	Rabinowitz et al.			
78.	08/12/2004	US 2004/0156791	Rabinowitz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 00065.01R	Application Number: 10/712,365
	Applicant: HALE et al.	
	Filing Date: 11/12/2003	Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." <i>European Journal of Pharmaceutics and Biopharmaceutics</i> Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." <i>Cardiovascular Research</i> 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" <i>International Journal of Pharmaceutics</i> 204:35-41.
	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." <i>Am J Respir Crit Care Med</i> Vol. 161: 1963-1967.
	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." <i>Am. Rev. Respir. Dis.</i> 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." <i>Br J Clin Pharmacol</i> Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5' Monophosphate Airway Responsiveness with Inhaled Furosemide and Bumetanide in Asthma." <i>J. Allergy Clin. Immunol.</i> 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oxygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." <i>Am J Physiol Renal Physiol.</i> 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." <i>Journal of Pain and Symptom Management</i> Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	